We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lutein and Alzheimer's Disease Study (LAD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2008 by Oregon Health and Science University.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00596024
First Posted: January 16, 2008
Last Update Posted: January 16, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Oregon Partnership for Alzheimer's Research
Information provided by:
Oregon Health and Science University
January 4, 2008
January 16, 2008
January 16, 2008
December 2007
December 2008   (Final data collection date for primary outcome measure)
oxidative damage markers [ Time Frame: 3 months ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Lutein and Alzheimer's Disease Study
Lutein and Oxidative Stress in Alzheimer's Disease - A Pilot Study

Oxidative damage by free radicals may be involved in causing Alzheimer's disease (AD). Free radicals may lead to death of nerve cells and decline in brain function. Certain antioxidants may suppress this free radical damage associated with AD. Carotenoids are a family of naturally occurring antioxidants that have important functions for human health. Carotenoids are known to reduce oxidative damage, but their effects have not been studied in AD patients.

The objective of the study is to examine whether lutein supplementation helps to reduce oxidative damage from free radicals in AD patients.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Alzheimer's Disease
  • Dietary Supplement: lutein/zeaxanthin
    daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
  • Dietary Supplement: placebo
    placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
  • Experimental: 1
    Daily Lutein/zeaxanthin supplementation with a meal
    Intervention: Dietary Supplement: lutein/zeaxanthin
  • Placebo Comparator: 2
    Intervention: Dietary Supplement: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
16
Not Provided
December 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosed with moderately severe Alzheimer's disease
Sexes Eligible for Study: All
55 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00596024
LAD
Alzheimer research fund
No
Not Provided
Not Provided
Wei Wang, PhD, Oregon Health and Science University
Oregon Health and Science University
Oregon Partnership for Alzheimer's Research
Principal Investigator: Wei Wang, PhD Oregon Health and Science University
Oregon Health and Science University
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top